Search results
Aug 6, 2024 · Daiichi Sankyo is a company that discovers, develops and delivers new standards of care for various diseases. Learn about its products, pipeline, initiatives, corporate governance, sustainability and more.
- Research & Development
Research & Development - Daiichi Sankyo
- Sustainability
Daiichi Sankyo is on a journey to think, act, and operate...
- Careers
At Daiichi Sankyo, we're dedicated to building a culture in...
- Our Pipeline
Our Pipeline - Daiichi Sankyo
- Daiichi Sankyo
Marketing of pharmaceuticals (Daiichi Sankyo Europe Group)...
- Investors
Investors - Daiichi Sankyo
- Our Mission & Strengths
In addition, we have established the Daiichi Sankyo Group...
- Our People
Our People - Daiichi Sankyo
- Research & Development
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan.
Daiichi Sankyo provides innovative products and services in 29 countries/regions around the world. Learn about its mission, vision, values, strengths, R&D capabilities, and history as a pharma innovator.
Daiichi Sankyo is a result of the merger of Daiichi Pharmaceutical and Sankyo in 2005. It delivers innovative products that enhance the lives of millions of people around the world with its Purpose: “To contribute to the enrichment of quality of life around the world”.
Aug 6, 2024 · Daiichi Sankyo is solely responsible for manufacturing and supply. About Daiichi Sankyo. Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Aug 6, 2024 · About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to ...
Oct 20, 2023 · TOKYO, Oct 19 (Reuters) - Drugmaker Merck (MRK.N) will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up...